$2.02
3.59% yesterday
NYSE, May 20, 10:02 pm CET
ISIN
US43157M1027
Symbol
HLVX
Sector
Industry

HilleVax Stock price

$2.02
+0.36 21.69% 1M
+0.23 12.85% 6M
-0.05 2.42% YTD
-12.47 86.06% 1Y
-8.15 80.14% 3Y
-17.07 89.42% 5Y
-17.07 89.42% 10Y
NYSE, Closing price Tue, May 20 2025
+0.07 3.59%
ISIN
US43157M1027
Symbol
HLVX
Sector
Industry

Key metrics

Market capitalization $101.29m
Enterprise Value $-34.21m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.38
P/B ratio (TTM) P/B ratio 0.67
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-80.09m
Free Cash Flow (TTM) Free Cash Flow $-88.88m
Cash position $159.54m
EPS (TTM) EPS $-2.16
P/E forward negative
Short interest 8.75%
Show more

Is HilleVax a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

HilleVax Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a HilleVax forecast:

2x Hold
100%

Analyst Opinions

2 Analysts have issued a HilleVax forecast:

Hold
100%

Financial data from HilleVax

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs 2.98 2.98
19% 19%
-
-2.98 -2.98
19% 19%
-
- Selling and Administrative Expenses 20 20
18% 18%
-
- Research and Development Expense 54 54
51% 51%
-
-77 -77
43% 43%
-
- Depreciation and Amortization 2.98 2.98
19% 19%
-
EBIT (Operating Income) EBIT -80 -80
42% 42%
-
Net Profit -107 -107
26% 26%
-

In millions USD.

Don't miss a Thing! We will send you all news about HilleVax directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

HilleVax Stock News

Neutral
GlobeNewsWire
13 days ago
$159.5 million of cash, cash equivalents and marketable securities as of March 31, 2025 The company is exploring the potential for continued development of its norovirus vaccine candidates inadults as well as business development related activities and other strategic alternatives BOSTON, May 08, 2025 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company ...
Neutral
Business Wire
about one month ago
PALO ALTO, Calif.--(BUSINESS WIRE)--Frazier Life Sciences (FLS), a longstanding investment firm focused on innovative therapeutics, today announced the appointment of Aditya Kohli, Ph.D., to Partner. Since joining FLS in 2016, Dr. Kohli has played a foundational role in company creation, co-founding six life sciences companies, including HilleVax (NASDAQ: HLVX, IPO in 2022), Phathom Pharmaceuti...
Neutral
GlobeNewsWire
about 2 months ago
$171.4 million of cash, cash equivalents and marketable securities as of December 31, 2024 The company is exploring the potential for continued development of its norovirus vaccine candidates in adults as well as business development related activities and other strategic alternatives BOSTON, March 28, 2025 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical co...

Company Profile

HilleVax, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing novel vaccines. Its pipeline includes Norovirus and HIL-214. The company was founded by Maurice Hilleman and Tadataka Yamada on March 25, 2020 and is headquartered in Boston, MA.

Head office United States
CEO Robert Hershberg
Employees 14
Founded 2020
Website www.hillevax.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today